Jose-Miguel Yamal1, Imoigele P Aisiku2, H Julia Hannay3, Frances A Brito1, Claudia S Robertson4. 1. Department of Biostatistics and Data Science, The University of Texas School of Public Health, Houston, Texas. 2. Department of Emergency Medicine, Harvard Medical School/Brigham and Women's Hospital, Boston, Massachusetts. 3. Department of Psychology and Texas Institute for Measurement Evaluation and Statistics (TIMES), University of Houston, Houston Texas. 4. Department of Neurosurgery, Baylor College of Medicine, Houston, Texas.
Abstract
BACKGROUND: An early acute marker of long-term neurological outcome would be useful to help guide clinical decision making and therapeutic effectiveness after severe traumatic brain injury (TBI). We investigated the utility of the Disability Rating Scale (DRS) as early as 1 wk after TBI as a predictor of favorable 6-mo Glasgow Outcome Scale extended (GOS-E). OBJECTIVE: To determine the predictability of a favorable 6-mo GOS-E using the DRS measured during weeks 1 to 4 of injury. METHODS: The study is a sub analysis of patients enrolled in the Epo Severe TBI Trial (n = 200) to train and validate L1-regularized logistic regression models. DRS was collected at weeks 1 to 4 and GOS-E at 6 mo. RESULTS: The average area under the receiver operating characteristic curve was 0.82 for the model with baseline demographic and injury severity variables and week 1 DRS and increased to 0.88 when including weekly DRS until week 4. CONCLUSION: This study suggests that week 1 to 4 DRS may be predictors of favorable 6-mo outcome in severe TBI patients and thus useful both for clinical prognostication as well as surrogate endpoints for adaptive clinical trials.
BACKGROUND: An early acute marker of long-term neurological outcome would be useful to help guide clinical decision making and therapeutic effectiveness after severe traumatic brain injury (TBI). We investigated the utility of the Disability Rating Scale (DRS) as early as 1 wk after TBI as a predictor of favorable 6-mo Glasgow Outcome Scale extended (GOS-E). OBJECTIVE: To determine the predictability of a favorable 6-mo GOS-E using the DRS measured during weeks 1 to 4 of injury. METHODS: The study is a sub analysis of patients enrolled in the Epo Severe TBI Trial (n = 200) to train and validate L1-regularized logistic regression models. DRS was collected at weeks 1 to 4 and GOS-E at 6 mo. RESULTS: The average area under the receiver operating characteristic curve was 0.82 for the model with baseline demographic and injury severity variables and week 1 DRS and increased to 0.88 when including weekly DRS until week 4. CONCLUSION: This study suggests that week 1 to 4 DRS may be predictors of favorable 6-mo outcome in severe TBI patients and thus useful both for clinical prognostication as well as surrogate endpoints for adaptive clinical trials.
Authors: Andrew I R Maas; David K Menon; P David Adelson; Nada Andelic; Michael J Bell; Antonio Belli; Peter Bragge; Alexandra Brazinova; András Büki; Randall M Chesnut; Giuseppe Citerio; Mark Coburn; D Jamie Cooper; A Tamara Crowder; Endre Czeiter; Marek Czosnyka; Ramon Diaz-Arrastia; Jens P Dreier; Ann-Christine Duhaime; Ari Ercole; Thomas A van Essen; Valery L Feigin; Guoyi Gao; Joseph Giacino; Laura E Gonzalez-Lara; Russell L Gruen; Deepak Gupta; Jed A Hartings; Sean Hill; Ji-Yao Jiang; Naomi Ketharanathan; Erwin J O Kompanje; Linda Lanyon; Steven Laureys; Fiona Lecky; Harvey Levin; Hester F Lingsma; Marc Maegele; Marek Majdan; Geoffrey Manley; Jill Marsteller; Luciana Mascia; Charles McFadyen; Stefania Mondello; Virginia Newcombe; Aarno Palotie; Paul M Parizel; Wilco Peul; James Piercy; Suzanne Polinder; Louis Puybasset; Todd E Rasmussen; Rolf Rossaint; Peter Smielewski; Jeannette Söderberg; Simon J Stanworth; Murray B Stein; Nicole von Steinbüchel; William Stewart; Ewout W Steyerberg; Nino Stocchetti; Anneliese Synnot; Braden Te Ao; Olli Tenovuo; Alice Theadom; Dick Tibboel; Walter Videtta; Kevin K W Wang; W Huw Williams; Lindsay Wilson; Kristine Yaffe Journal: Lancet Neurol Date: 2017-11-06 Impact factor: 44.182
Authors: Guy L Clifton; Alex Valadka; David Zygun; Christopher S Coffey; Pamala Drever; Sierra Fourwinds; L Scott Janis; Elizabeth Wilde; Pauline Taylor; Kathy Harshman; Adam Conley; Ava Puccio; Harvey S Levin; Stephen R McCauley; Richard D Bucholz; Kenneth R Smith; John H Schmidt; James N Scott; Howard Yonas; David O Okonkwo Journal: Lancet Neurol Date: 2010-12-17 Impact factor: 44.182
Authors: Joukje van der Naalt; Marieke E Timmerman; Myrthe E de Koning; Harm J van der Horn; Myrthe E Scheenen; Bram Jacobs; Gerard Hageman; Tansel Yilmaz; Gerwin Roks; Jacoba M Spikman Journal: Lancet Neurol Date: 2017-06-13 Impact factor: 44.182
Authors: Stephen R McCauley; Elisabeth A Wilde; Paolo Moretti; Marianne C Macleod; Claudia Pedroza; Pamala Drever; Sierra Fourwinds; Melisa L Frisby; Sue R Beers; James N Scott; Jill V Hunter; Elfrides Traipe; Alex B Valadka; David O Okonkwo; David A Zygun; Ava M Puccio; Guy L Clifton Journal: J Neurotrauma Date: 2013-08-02 Impact factor: 5.269
Authors: Philip Pallmann; Alun W Bedding; Babak Choodari-Oskooei; Munyaradzi Dimairo; Laura Flight; Lisa V Hampson; Jane Holmes; Adrian P Mander; Lang'o Odondi; Matthew R Sydes; Sofía S Villar; James M S Wason; Christopher J Weir; Graham M Wheeler; Christina Yap; Thomas Jaki Journal: BMC Med Date: 2018-02-28 Impact factor: 8.775
Authors: Ewout W Steyerberg; Nino Mushkudiani; Pablo Perel; Isabella Butcher; Juan Lu; Gillian S McHugh; Gordon D Murray; Anthony Marmarou; Ian Roberts; J Dik F Habbema; Andrew I R Maas Journal: PLoS Med Date: 2008-08-05 Impact factor: 11.069